RxDoctor Payments DataLook up a doctor →

Biswajit Kar, MD

Interventional Cardiology · Houston, TXNPI 1790865053

Payments from drug & device makers

$784,633in general payments, 2019–2025

Across 209 payments — averaging $3754.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$701K
  • Boston Scientific$50K
  • Abbott$14K
  • Saranas, Inc.$12K
  • Transmedics, Inc.$3K
  • Medtronic$2K
  • plus $3K from 25 others

What the payments were for

  • Consulting fees$5,62526%
  • Travel & lodging$8,55040%
  • Food & beverage$6,76232%
  • Education$580%
  • Other$2821%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$784,633 in reported general payments places this provider in the 95th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$133,136
Medicare patients
283
Services billed
548

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan304$330,089
JardianceEmpagliflozin246$246,631
EliquisApixaban186$195,430
FarxigaDapagliflozin Propanediol105$93,252
KineretAnakinra13$69,270
Repatha SureclickEvolocumab79$58,169
XareltoRivaroxaban49$48,152
OzempicSemaglutide38$37,967
Praluent PenAlirocumab43$27,285
Repatha SyringeEvolocumab27$22,178
SynjardyEmpagliflozin/Metformin Hcl16$20,435
BrilintaTicagrelor15$15,798
Icosapent Ethyl34$14,828
Ranolazine ErRanolazine47$11,378
PrografTacrolimus24$6,321

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$144$330,089304 claims
PfizerEliquis$25$195,430186 claims
AstraZenecaFarxiga, Brilinta$37$109,050120 claims
Johnson & JohnsonXarelto$99$48,15249 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →